Carpinteria-based Procore Technologies, a construction management software company, announced its results for the second quarter on Aug. 1. For the quarter ended June 30, Procore’s revenue was $284 million, an increase of 24% year-over-year. Moreover, the company, which has never achieved a profit, substantially cut its net loss in the second quarter, suffering a loss Read More →
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
The common saying goes “The third time’s a charm” but for Nima Farzan, he’s looking to go 3-for-3 successfully running biotechnology companies. On July 22, Farzan was appointed to be Latigo Biotherapeutics, a clinical-stage biotech company based in Thousand Oaks, first CEO. Farzan’s experience spans more than two decades long in the biopharmaceutical industry, including being the Read More →
Latigo Biotherapeutics, a clinical-stage biotech company based in Thousand Oaks, announced that it has appointed Nima Farzan to be its CEO. Announced July 22, Farzan brings a “strong track record” with more than two decades of leadership experience in the biopharmaceutical industry. Farzan is also Latigo’s first CEO as he replaces Desmond Padhi, operating partner Read More →